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Outline
 International influenza activity update
 Recent U.S. influenza activity
 Southern Hemisphere vaccine recommendations
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Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories,
National Summary, September 30, 2018 – October 12, 2019
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Genetic and Antigenic Characterization of Influenza 
Viruses Collected May 19 – September 28, 2019
 Data includes viruses submitted by US and international laboratories and 
tested at CDC
 A (H1N1)pdm09: all viruses tested belong to genetic subclade 6B.1A and 
96% are similar to the cell-culture propagated 2019-20 Northern 
Hemisphere vaccine virus component (A/Brisbane/02/2018)
 B/Yamagata lineage: All viruses tested belonged to Y3 genetic clade and all  
are similar to the cell-culture propagated 2019-20 Northern Hemisphere 
vaccine virus component (B/Phuket/3073/2013)
Genetic and Antigenic Characterization of Influenza 
A(H3N2) Viruses Collected May 19 – September 28, 2019
 Recently tested A(H3N2) viruses (n=427) belong to either clades 3C.2a 
(83%) or 3C.3a (17%)
 There are multiple subclades within the 3C.2a clade circulating
– The majority belong to subclade 3C.2a1
 3C.2a1 viruses predominated in Australia but 3C.3a viruses predominated 
among H3 viruses in South America
 70% of antigenically characterized H3 viruses are similar to the cell-culture 
propagated 2019-20 Northern Hemisphere vaccine virus component 
(A/Kansas/14/2017 – 3C.3a) 
 While ferret antisera clearly distinguish antigenic differences between 
3C.2a and 3C.3a viruses, there is some cross reactivity
Genetic and Antigenic Characterization of Influenza 
B/Victoria Viruses Collected May 19 – September 28, 2019
 B/Victoria lineage viruses belong to either clade V1A (4%), or subclades 
V1A.1 (24%) and V1A-3Del (72%)
 V1A.1 viruses antigenically characterized were similar to the cell culture-
propagated 2019-20 Northern Hemisphere vaccine component 
(B/Colorado/06/2017)
 Ferret antisera raised against recent V1A.1 viruses had reduced reactivity 
with V1A and V1A-3Del viruses indicating some antigenic differences 
between the B/Victoria lineages subclades
– However, sera from humans vaccinated with V1A.1 virus cross reacted 
well with V1A-3Del viruses
Percentage of Visits for Influenza-like Illness (ILI) Reported by 
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
Weekly National Summary, 2019-2020 and Selected Previous Seasons





Pneumonia and Influenza Mortality from
the National Center for Health Statistics Mortality Surveillance System











Deaths Reported Current WeekDeaths Reported Previous Weeks
Influenza-Associated Pediatric Deaths
by Week of Death, 2016-2017 season to 2019-2020 season
2016-2017
Number of Deaths = 110
2017-2018
Number of Deaths = 187
2019-2020
Number of Deaths = 0
Recommendation for 2020 Southern Hemisphere 
Influenza Vaccine
 It is recommended that the following viruses be used for trivalent 






A/South Australia/34/2019 (H3N2)-like virus
B/Washington/02/2019-like virus (B/Victoria lineage)
 For quadrivalent vaccines containing 2 B components:
Above 3, plus B/Phuket/3073/2013-like virus (B/Yamagata lineage)
Summary
 Influenza activity remains low in the US overall
 Numbers are small, but so far, influenza A(H3N2) viruses are predominant 
in the US overall but this varies by region
– Too early to tell what viruses will be predominant for the season
 While 2 of the 4 vaccine components were updated for the Southern 
Hemisphere, the components selected for the 2019-20 Northern 
Hemisphere vaccine, at this time, look appropriate for our season
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